Cancer - New-wiki

Novel	Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
Novel Novel	Symbols ANXA2 and SMAD6	Name 1 annexin A2	Name2 SMAD family member 6	Pathway 1 Smooth Muscle Contraction Neutrophil degranulation Dissolution of Fibrin Clot Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells Developmental Lineage of Pancreatic Ductal Cells	Pathway 2 Signaling by BMP RUNX2 regulates bone development	Drugs 1 Tenecteplase Fluocinolone acetonide Lanoteplase Artenimol	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols TNF and TNXB	Name 1 tumor necrosis factor	Name2 tenascin XB	Pathway 1 Transcriptional regulation of white adipocyte differentiation TNFR1-induced proapoptotic signaling Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway TNFR1-mediated ceramide production TNFR2 non-canonical NF-kB pathway Interleukin-10 signaling Interleukin-4 and Interleukin-13 signaling TNF signaling Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells)	Pathway 2 ECM proteoglycans	Drugs 1 Etanercept Adalimumab Infliximab Chloroquine Epinephrine Pseudoephedrine Clenbuterol Pranlukast Amrinone Trichostatin A Afelimomab YSIL6 SD118 PN0621 OMS-103HP Talmapimod VX-702 Atiprimod CRx-139 CYT007-TNFQb Andrographolide Ethyl pyruvate AME-527 PR-104 Plinabulin Dexanabinol Onercept Golimumab Certolizumab pegol Pomalidomide Polaprezinc Foreskin fibroblast (neonatal) Foreskin keratinocyte (neonatal) Bryostatin 1 Binimetinib Dilmapimod Glycyrrhizic acid	Drugs 2	Diseases 1 Graft-versus-host disease Systemic lupus erythematosus Allograft rejection Asthma	Diseases 2 Ehlers-Danlos syndrome (EDS), including: EDS classical type (EDS1/2); EDS hypermobility type (EDS3); EDS vascular type (EDS4); EDS kyphoscoliosis type (EDS6); EDS arthrochalasia type (EDS7A/7B); EDS dermatospraxis type (EDS7C); EDS autosomal recessive cardiac valvular form (EDSCV); EDS musculocontractural type (EDSMC); EDS progeroid form (EDSP); Tenascin-X deficiency (TNXD); Brittle cornea syndrome (EDS6B); EDS-like spondylocheiro dysplasia (SCD-EDS)
Novel Novel	Symbols JAK1 and P2RY1	Name 1 Janus kinase 1	Name2 purinergic receptor P2Y1	Pathway 1 Interleukin-6 signaling Interleukin-6 signaling MAPK3 (ERK1) activation MAPK1 (ERK2) activation ISG15 antiviral mechanism Interleukin-7 signaling Interleukin-7 signaling Other interleukin signaling RAF/MAP kinase cascade Interleukin-10 signaling Interleukin-4 and Interleukin-13 signaling IL-6-type cytokine receptor ligand interactions Interferon gamma signaling Regulation of IFNG signaling Regulation of IFNG signaling Interleukin-20 family signaling Interleukin-15 signaling Interleukin-15 signaling Interleukin-35 Signalling Interleukin-9 signaling Interleukin-2 signaling Interleukin-12 signaling Interleukin-12 signaling Interleukin-27 signaling Interleukin-27 signaling Interleukin-21 signaling Interferon alpha/beta signaling Interleukin receptor SHC signaling Regulation of IFNA/IFNB signaling Regulation of IFNA/IFNB signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Potential therapeutics for SARS Inactivation of CSF3 (G-CSF) signaling Inactivation of CSF3 (G-CSF) signaling SARS-CoV-2 activates/modulates innate and adaptive immune responses IFNG signaling activates MAPKs Evasion by RSV of host interferon responses PD-L1(CD274) glycosylation and translocation to plasma membrane	Pathway 2 G alpha (q) signalling events P2Y receptors ADP signalling through P2Y purinoceptor 1 ADP signalling through P2Y purinoceptor 1	Drugs 1 Myricetin 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one Ruxolitinib Tofacitinib Baricitinib Fostamatinib Fedratinib Filgotinib Abrocitinib Upadacitinib Pralsetinib Ivarmacitinib	Drugs 2 Promethazine	Diseases 1	Diseases 2
Novel Novel	Symbols LYN and TRPA1	Name 1 LYN proto-oncogene, Src family tyrosine kinase	Name2 transient receptor potential cation channel subfamily A member 1	Pathway 1 GPVI-mediated activation cascade Signaling by SCF-KIT Signaling by SCF-KIT Regulation of KIT signaling Cell surface interactions at the vascular wall FCGR activation PECAM1 interactions Fc epsilon receptor (FCERI) signaling Fc epsilon receptor (FCERI) signaling EPH-Ephrin signaling Role of LAT2/NTAL/LAB on calcium mobilization Role of LAT2/NTAL/LAB on calcium mobilization FCERI mediated MAPK activation FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization FCERI mediated NF-kB activation Co-stimulation by CD28 Co-inhibition by CTLA4 EPHB-mediated forward signaling EPHB-mediated forward signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse EPH-ephrin mediated repulsion of cells Dectin-2 family CD209 (DC-SIGN) signaling CD22 mediated BCR regulation Cyclin D associated events in G1 Platelet Adhesion to exposed collagen Signaling by Erythropoietin Signaling by Erythropoietin Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phospholipase C gamma (PLCG) Erythropoietin activates STAT5 Erythropoietin activates RAS Erythropoietin activates RAS Regulation of signaling by CBL Regulation of signaling by CBL FCGR3A-mediated IL10 synthesis FCGR3A-mediated phagocytosis Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Signaling by CSF1 (M-CSF) in myeloid cells Inactivation of CSF3 (G-CSF) signaling Inactivation of CSF3 (G-CSF) signaling Growth hormone receptor signaling Growth hormone receptor signaling Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Pathway 2 TRP channels	Drugs 1 Dasatinib 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine Bosutinib Ponatinib Nintedanib Fostamatinib	Drugs 2 Levomenthol Camphor Cannabidiol Butamben (S)-camphor Tetrahydrocannabivarin Medical Cannabis Nabiximols Cannabidivarin	Diseases 1	Diseases 2
Novel Novel	Symbols EHBP1 and WDPCP	Name 1 EH domain binding protein 1	Name2 WD repeat containing planar cell polarity effector	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols GRM3 and ZNF804B	Name 1 glutamate metabotropic receptor 3	Name2 zinc finger protein 804B	Pathway 1 G alpha (i) signalling events Class C/3 (Metabotropic glutamate/pheromone receptors)	Pathway 2 Generic Transcription Pathway	Drugs 1 LY2140023	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols IL6 and DNAH11	Name 1 interleukin 6	Name2 dynein axonemal heavy chain 11	Pathway 1 Interleukin-6 signaling MAPK3 (ERK1) activation MAPK1 (ERK2) activation Senescence-Associated Secretory Phenotype (SASP) Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Interleukin-10 signaling Interleukin-4 and Interleukin-13 signaling Transcriptional Regulation by VENTX Post-translational protein phosphorylation ADORA2B mediated anti-inflammatory cytokines production CD163 mediating an anti-inflammatory response	Pathway 2	Drugs 1 Ginseng YSIL6 VX-702 Atiprimod CRx-139 Andrographolide Siltuximab Polaprezinc Foreskin fibroblast (neonatal) Foreskin keratinocyte (neonatal) Binimetinib Dilmapimod Olokizumab	Drugs 2	Diseases 1 Graft-versus-host disease	Diseases 2
Novel Novel	Symbols DRD2 and IL10RA	Name 1 dopamine receptor D2	Name2 interleukin 10 receptor subunit alpha	Pathway 1 Dopamine receptors	Pathway 2 Interleukin-10 signaling Nuclear events stimulated by ALK signaling in cancer	Drugs 1 Amphetamine Ziprasidone Cabergoline Ropinirole Dihydroergotamine Olanzapine Clozapine Thiethylperazine Sulpiride Loxapine Remoxipride Pramipexole Promazine Prochlorperazine Droperidol Imipramine Chlorpromazine Buspirone Haloperidol Triflupromazine Nortriptyline Amoxapine Lamotrigine Cinnarizine Lisuride Fluphenazine Thioridazine Ergotamine Apomorphine Paroxetine Trimipramine Risperidone Propiomazine Minaprine Trifluoperazine Perphenazine Flupentixol Amantadine Mesoridazine Maprotiline Dopamine Carphenazine Memantine Ergoloid mesylate Acetophenazine Promethazine Pimozide Desipramine Escitalopram Domperidone Pergolide Bromocriptine Ketamine Quetiapine Metoclopramide Levodopa Aripiprazole Chlorprothixene Paliperidone Yohimbine Methotrimeprazine Alizapride Rolicyclidine Acepromazine Molindone Pipotiazine Thioproperazine Thiothixene Zuclopenthixol Aniracetam Fluspirilene Tetrabenazine Brasofensine Bifeprunox Bicifadine Itopride Iloperidone Rotigotine BL-1020 Norclozapine Amitifadine Cariprazine Lumateperone YKP-1358 Sertindole Mianserin Asenapine Ocaperidone Amisulpride Sarizotan Sumanirole Nandrolone decanoate Lurasidone Perospirone Bromopride Quinagolide Brexpiprazole Etoperidone AS-8112 Blonanserin Melperone Zotepine Pipamperone Dihydro-alpha-ergocryptine Epicriptine Pardoprunox Tetrahydropalmatine Piribedil Raclopride JNJ-37822681 Tiapride Dihydroergocristine Aripiprazole lauroxil	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols NIN and TXNDC16	Name 1 ninein	Name2 thioredoxin domain containing 16	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols IRAK1 and LDHD	Name 1 interleukin 1 receptor associated kinase 1	Name2 lactate dehydrogenase D	Pathway 1 PIP3 activates AKT signaling MyD88:MAL(TIRAP) cascade initiated on plasma membrane NOD1/2 Signaling Pathway p75NTR recruits signalling complexes p75NTR recruits signalling complexes NF-kB is activated and signals survival TAK1-dependent IKK and NF-kappa-B activation activated TAK1 mediates p38 MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Transcriptional Regulation by MECP2 Interleukin-1 signaling IRAK1 recruits IKK complex SARS-CoV-2 activates/modulates innate and adaptive immune responses TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation MyD88 dependent cascade initiated on endosome MyD88 cascade initiated on plasma membrane	Pathway 2 Mitochondrial protein import Mitochondrial protein import Mitochondrial protein degradation	Drugs 1 Fostamatinib	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols CD48 and EFNA3	Name 1 CD48 molecule	Name2 ephrin A3	Pathway 1 Cell surface interactions at the vascular wall	Pathway 2 EPH-Ephrin signaling EPH-Ephrin signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse EPH-ephrin mediated repulsion of cells EPH-ephrin mediated repulsion of cells	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols ST3GAL3 and VTI1A	Name 1 ST3 beta-galactoside alpha-2,3-sialyltransferase 3	Name2 vesicle transport through interaction with t-SNAREs 1A	Pathway 1 Pre-NOTCH Processing in Golgi Keratan sulfate biosynthesis Defective ST3GAL3 causes MCT12 and EIEE15 Sialic acid metabolism Lewis blood group biosynthesis Maturation of protein 3a Maturation of spike protein Maturation of protein 3a Termination of O-glycan biosynthesis Glycosphingolipid biosynthesis	Pathway 2 Intra-Golgi traffic Retrograde transport at the Trans-Golgi-Network	Drugs 1	Drugs 2	Diseases 1 Nonsyndromic autosomal recessive mental retardation (NS-ARMR)	Diseases 2
Novel Novel	Symbols ATP6AP1 and CTAG1B	Name 1 ATPase H+ transporting accessory protein 1	Name2 cancer/testis antigen 1B	Pathway 1 Insulin receptor recycling RHOA GTPase cycle Transferrin endocytosis and recycling Ion channel transport	Pathway 2	Drugs 1 Tiludronic acid	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols ALK and TSPAN16	Name 1 ALK receptor tyrosine kinase	Name2 tetraspanin 16	Pathway 1 Signaling by ALK Signaling by ALK ALK mutants bind TKIs ASP-3026-resistant ALK mutants NVP-TAE684-resistant ALK mutants alectinib-resistant ALK mutants brigatinib-resistant ALK mutants ceritinib-resistant ALK mutants crizotinib-resistant ALK mutants lorlatinib-resistant ALK mutants Signaling by ALK fusions and activated point mutants MDK and PTN in ALK signaling MDK and PTN in ALK signaling	Pathway 2	Drugs 1 ATP Crizotinib Ceritinib Alectinib Fostamatinib Lorlatinib Gilteritinib Brigatinib	Drugs 2	Diseases 1 Non-small cell lung cancer	Diseases 2
Novel Novel	Symbols C5 and SLC10A2	Name 1 complement C5	Name2 solute carrier family 10 member 2	Pathway 1 Terminal pathway of complement Activation of C3 and C5 Peptide ligand-binding receptors G alpha (i) signalling events Regulation of Complement cascade	Pathway 2 Recycling of bile acids and salts	Drugs 1 Human immunoglobulin G Eculizumab Zinc Copper Ravulizumab Zinc acetate Zinc chloride Zinc sulfate, unspecified form Zilucoplan Vilobelimab	Drugs 2 Volixibat Maralixibat Odevixibat	Diseases 1 Late complement pathway defects, including the following seven diseases: C5 deficiency; C6 deficiency; C7 deficiency; C8 alpha-chain deficiency; C8 beta-chain deficiency; C8 gamma-chain deficiency; C9 deficiency	Diseases 2 Primary bile acid malabsorption
Novel Novel	Symbols ICAM1 and MC1R	Name 1 intercellular adhesion molecule 1	Name2 melanocortin 1 receptor	Pathway 1 Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Integrin cell surface interactions Interleukin-10 signaling Interleukin-4 and Interleukin-13 signaling Interferon gamma signaling	Pathway 2 Peptide ligand-binding receptors G alpha (s) signalling events Transcriptional and post-translational regulation of MITF-M expression and activity	Drugs 1 Natalizumab Hyaluronic acid Nafamostat	Drugs 2 Afamelanotide CZEN 002 Bremelanotide	Diseases 1 Allograft rejection	Diseases 2
Novel Novel	Symbols RAE1 and RTEL1	Name 1 ribonucleic acid export 1	Name2 regulator of telomere elongation helicase 1	Pathway 1 ISG15 antiviral mechanism Transport of the SLBP independent Mature mRNA Transport of the SLBP Dependant Mature mRNA Transport of Mature mRNA Derived from an Intronless Transcript Transport of Mature mRNA derived from an Intron-Containing Transcript Rev-mediated nuclear export of HIV RNA Transport of Ribonucleoproteins into the Host Nucleus NS1 Mediated Effects on Host Pathways Viral Messenger RNA Synthesis NEP/NS2 Interacts with the Cellular Export Machinery Regulation of Glucokinase by Glucokinase Regulatory Protein Nuclear import of Rev protein Vpr-mediated nuclear import of PICs IPs transport between nucleus and cytosol IP3 and IP4 transport between cytosol and nucleus IP6 and IP7 transport between cytosol and nucleus snRNP Assembly SUMOylation of DNA damage response and repair proteins SUMOylation of ubiquitinylation proteins Nuclear Pore Complex (NPC) Disassembly Regulation of HSF1-mediated heat shock response SUMOylation of SUMOylation proteins SUMOylation of chromatin organization proteins SUMOylation of RNA binding proteins SUMOylation of DNA replication proteins SUMOylation of DNA replication proteins Transcriptional regulation by small RNAs Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) tRNA processing in the nucleus HCMV Early Events HCMV Late Events SARS-CoV-2 activates/modulates innate and adaptive immune responses	Pathway 2 Telomere Extension By Telomerase Cytosolic iron-sulfur cluster assembly Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols TRIM31 and BTNL2	Name 1 tripartite motif containing 31	Name2 butyrophilin like 2	Pathway 1 Interferon gamma signaling	Pathway 2 Butyrophilin (BTN) family interactions	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols ACTR1A and CNNM2	Name 1 actin related protein 1A	Name2 cyclin and CBS domain divalent metal cation transport mediator 2	Pathway 1 MHC class II antigen presentation Regulation of PLK1 Activity at G2/M Transition HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Anchoring of the basal body to the plasma membrane COPI-mediated anterograde transport COPI-independent Golgi-to-ER retrograde traffic AURKA Activation by TPX2	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols FBN1 and SECISBP2L	Name 1 fibrillin 1	Name2 SECIS binding protein 2 like	Pathway 1 Degradation of the extracellular matrix Degradation of the extracellular matrix Elastic fibre formation Molecules associated with elastic fibres Molecules associated with elastic fibres Integrin cell surface interactions TGF-beta receptor signaling activates SMADs Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Post-translational protein phosphorylation	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Geleophysic dysplasia Weill-Marchesani syndrome, including: Weill-Marchesani syndrome; Weill-Marchesani-like syndrome Shprintzen-Goldberg syndrome Ectopia lentis MASS phenotype Marfan syndrome, including: Marfan syndrome (MFS); Neonatal MFS; Atypically severe MFS; New variant of MFS	Diseases 2
Novel	Symbols ANXA2 and SMAD6	Name 1 annexin A2	Name2 SMAD family member 6	Pathway 1 Smooth Muscle Contraction Neutrophil degranulation Dissolution of Fibrin Clot Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells Developmental Lineage of Pancreatic Ductal Cells	Pathway 2 Signaling by BMP RUNX2 regulates bone development	Drugs 1 Tenecteplase Fluocinolone acetonide Lanoteplase Artenimol	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols TNF and TNXB	Name 1 tumor necrosis factor	Name2 tenascin XB	Pathway 1 Transcriptional regulation of white adipocyte differentiation TNFR1-induced proapoptotic signaling Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway TNFR1-mediated ceramide production TNFR2 non-canonical NF-kB pathway Interleukin-10 signaling Interleukin-4 and Interleukin-13 signaling TNF signaling Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells)	Pathway 2 ECM proteoglycans	Drugs 1 Etanercept Adalimumab Infliximab Chloroquine Epinephrine Pseudoephedrine Clenbuterol Pranlukast Amrinone Trichostatin A Afelimomab YSIL6 SD118 PN0621 OMS-103HP Talmapimod VX-702 Atiprimod CRx-139 CYT007-TNFQb Andrographolide Ethyl pyruvate AME-527 PR-104 Plinabulin Dexanabinol Onercept Golimumab Certolizumab pegol Pomalidomide Polaprezinc Foreskin fibroblast (neonatal) Foreskin keratinocyte (neonatal) Bryostatin 1 Binimetinib Dilmapimod Glycyrrhizic acid	Drugs 2	Diseases 1 Graft-versus-host disease Systemic lupus erythematosus Allograft rejection Asthma	Diseases 2 Ehlers-Danlos syndrome (EDS), including: EDS classical type (EDS1/2); EDS hypermobility type (EDS3); EDS vascular type (EDS4); EDS kyphoscoliosis type (EDS6); EDS arthrochalasia type (EDS7A/7B); EDS dermatospraxis type (EDS7C); EDS autosomal recessive cardiac valvular form (EDSCV); EDS musculocontractural type (EDSMC); EDS progeroid form (EDSP); Tenascin-X deficiency (TNXD); Brittle cornea syndrome (EDS6B); EDS-like spondylocheiro dysplasia (SCD-EDS)
Novel	Symbols JAK1 and P2RY1	Name 1 Janus kinase 1	Name2 purinergic receptor P2Y1	Pathway 1 Interleukin-6 signaling Interleukin-6 signaling MAPK3 (ERK1) activation MAPK1 (ERK2) activation ISG15 antiviral mechanism Interleukin-7 signaling Interleukin-7 signaling Other interleukin signaling RAF/MAP kinase cascade Interleukin-10 signaling Interleukin-4 and Interleukin-13 signaling IL-6-type cytokine receptor ligand interactions Interferon gamma signaling Regulation of IFNG signaling Regulation of IFNG signaling Interleukin-20 family signaling Interleukin-15 signaling Interleukin-15 signaling Interleukin-35 Signalling Interleukin-9 signaling Interleukin-2 signaling Interleukin-12 signaling Interleukin-12 signaling Interleukin-27 signaling Interleukin-27 signaling Interleukin-21 signaling Interferon alpha/beta signaling Interleukin receptor SHC signaling Regulation of IFNA/IFNB signaling Regulation of IFNA/IFNB signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Potential therapeutics for SARS Inactivation of CSF3 (G-CSF) signaling Inactivation of CSF3 (G-CSF) signaling SARS-CoV-2 activates/modulates innate and adaptive immune responses IFNG signaling activates MAPKs Evasion by RSV of host interferon responses PD-L1(CD274) glycosylation and translocation to plasma membrane	Pathway 2 G alpha (q) signalling events P2Y receptors ADP signalling through P2Y purinoceptor 1 ADP signalling through P2Y purinoceptor 1	Drugs 1 Myricetin 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one Ruxolitinib Tofacitinib Baricitinib Fostamatinib Fedratinib Filgotinib Abrocitinib Upadacitinib Pralsetinib Ivarmacitinib	Drugs 2 Promethazine	Diseases 1	Diseases 2
Novel	Symbols LYN and TRPA1	Name 1 LYN proto-oncogene, Src family tyrosine kinase	Name2 transient receptor potential cation channel subfamily A member 1	Pathway 1 GPVI-mediated activation cascade Signaling by SCF-KIT Signaling by SCF-KIT Regulation of KIT signaling Cell surface interactions at the vascular wall FCGR activation PECAM1 interactions Fc epsilon receptor (FCERI) signaling Fc epsilon receptor (FCERI) signaling EPH-Ephrin signaling Role of LAT2/NTAL/LAB on calcium mobilization Role of LAT2/NTAL/LAB on calcium mobilization FCERI mediated MAPK activation FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization FCERI mediated NF-kB activation Co-stimulation by CD28 Co-inhibition by CTLA4 EPHB-mediated forward signaling EPHB-mediated forward signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse EPH-ephrin mediated repulsion of cells Dectin-2 family CD209 (DC-SIGN) signaling CD22 mediated BCR regulation Cyclin D associated events in G1 Platelet Adhesion to exposed collagen Signaling by Erythropoietin Signaling by Erythropoietin Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phospholipase C gamma (PLCG) Erythropoietin activates STAT5 Erythropoietin activates RAS Erythropoietin activates RAS Regulation of signaling by CBL Regulation of signaling by CBL FCGR3A-mediated IL10 synthesis FCGR3A-mediated phagocytosis Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Signaling by CSF1 (M-CSF) in myeloid cells Inactivation of CSF3 (G-CSF) signaling Inactivation of CSF3 (G-CSF) signaling Growth hormone receptor signaling Growth hormone receptor signaling Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Pathway 2 TRP channels	Drugs 1 Dasatinib 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine Bosutinib Ponatinib Nintedanib Fostamatinib	Drugs 2 Levomenthol Camphor Cannabidiol Butamben (S)-camphor Tetrahydrocannabivarin Medical Cannabis Nabiximols Cannabidivarin	Diseases 1	Diseases 2
Novel	Symbols EHBP1 and WDPCP	Name 1 EH domain binding protein 1	Name2 WD repeat containing planar cell polarity effector	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols GRM3 and ZNF804B	Name 1 glutamate metabotropic receptor 3	Name2 zinc finger protein 804B	Pathway 1 G alpha (i) signalling events Class C/3 (Metabotropic glutamate/pheromone receptors)	Pathway 2 Generic Transcription Pathway	Drugs 1 LY2140023	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols IL6 and DNAH11	Name 1 interleukin 6	Name2 dynein axonemal heavy chain 11	Pathway 1 Interleukin-6 signaling MAPK3 (ERK1) activation MAPK1 (ERK2) activation Senescence-Associated Secretory Phenotype (SASP) Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Interleukin-10 signaling Interleukin-4 and Interleukin-13 signaling Transcriptional Regulation by VENTX Post-translational protein phosphorylation ADORA2B mediated anti-inflammatory cytokines production CD163 mediating an anti-inflammatory response	Pathway 2	Drugs 1 Ginseng YSIL6 VX-702 Atiprimod CRx-139 Andrographolide Siltuximab Polaprezinc Foreskin fibroblast (neonatal) Foreskin keratinocyte (neonatal) Binimetinib Dilmapimod Olokizumab	Drugs 2	Diseases 1 Graft-versus-host disease	Diseases 2
Novel	Symbols DRD2 and IL10RA	Name 1 dopamine receptor D2	Name2 interleukin 10 receptor subunit alpha	Pathway 1 Dopamine receptors	Pathway 2 Interleukin-10 signaling Nuclear events stimulated by ALK signaling in cancer	Drugs 1 Amphetamine Ziprasidone Cabergoline Ropinirole Dihydroergotamine Olanzapine Clozapine Thiethylperazine Sulpiride Loxapine Remoxipride Pramipexole Promazine Prochlorperazine Droperidol Imipramine Chlorpromazine Buspirone Haloperidol Triflupromazine Nortriptyline Amoxapine Lamotrigine Cinnarizine Lisuride Fluphenazine Thioridazine Ergotamine Apomorphine Paroxetine Trimipramine Risperidone Propiomazine Minaprine Trifluoperazine Perphenazine Flupentixol Amantadine Mesoridazine Maprotiline Dopamine Carphenazine Memantine Ergoloid mesylate Acetophenazine Promethazine Pimozide Desipramine Escitalopram Domperidone Pergolide Bromocriptine Ketamine Quetiapine Metoclopramide Levodopa Aripiprazole Chlorprothixene Paliperidone Yohimbine Methotrimeprazine Alizapride Rolicyclidine Acepromazine Molindone Pipotiazine Thioproperazine Thiothixene Zuclopenthixol Aniracetam Fluspirilene Tetrabenazine Brasofensine Bifeprunox Bicifadine Itopride Iloperidone Rotigotine BL-1020 Norclozapine Amitifadine Cariprazine Lumateperone YKP-1358 Sertindole Mianserin Asenapine Ocaperidone Amisulpride Sarizotan Sumanirole Nandrolone decanoate Lurasidone Perospirone Bromopride Quinagolide Brexpiprazole Etoperidone AS-8112 Blonanserin Melperone Zotepine Pipamperone Dihydro-alpha-ergocryptine Epicriptine Pardoprunox Tetrahydropalmatine Piribedil Raclopride JNJ-37822681 Tiapride Dihydroergocristine Aripiprazole lauroxil	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols NIN and TXNDC16	Name 1 ninein	Name2 thioredoxin domain containing 16	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols IRAK1 and LDHD	Name 1 interleukin 1 receptor associated kinase 1	Name2 lactate dehydrogenase D	Pathway 1 PIP3 activates AKT signaling MyD88:MAL(TIRAP) cascade initiated on plasma membrane NOD1/2 Signaling Pathway p75NTR recruits signalling complexes p75NTR recruits signalling complexes NF-kB is activated and signals survival TAK1-dependent IKK and NF-kappa-B activation activated TAK1 mediates p38 MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Transcriptional Regulation by MECP2 Interleukin-1 signaling IRAK1 recruits IKK complex SARS-CoV-2 activates/modulates innate and adaptive immune responses TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation MyD88 dependent cascade initiated on endosome MyD88 cascade initiated on plasma membrane	Pathway 2 Mitochondrial protein import Mitochondrial protein import Mitochondrial protein degradation	Drugs 1 Fostamatinib	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols CD48 and EFNA3	Name 1 CD48 molecule	Name2 ephrin A3	Pathway 1 Cell surface interactions at the vascular wall	Pathway 2 EPH-Ephrin signaling EPH-Ephrin signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse EPH-ephrin mediated repulsion of cells EPH-ephrin mediated repulsion of cells	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols ST3GAL3 and VTI1A	Name 1 ST3 beta-galactoside alpha-2,3-sialyltransferase 3	Name2 vesicle transport through interaction with t-SNAREs 1A	Pathway 1 Pre-NOTCH Processing in Golgi Keratan sulfate biosynthesis Defective ST3GAL3 causes MCT12 and EIEE15 Sialic acid metabolism Lewis blood group biosynthesis Maturation of protein 3a Maturation of spike protein Maturation of protein 3a Termination of O-glycan biosynthesis Glycosphingolipid biosynthesis	Pathway 2 Intra-Golgi traffic Retrograde transport at the Trans-Golgi-Network	Drugs 1	Drugs 2	Diseases 1 Nonsyndromic autosomal recessive mental retardation (NS-ARMR)	Diseases 2
Novel	Symbols ATP6AP1 and CTAG1B	Name 1 ATPase H+ transporting accessory protein 1	Name2 cancer/testis antigen 1B	Pathway 1 Insulin receptor recycling RHOA GTPase cycle Transferrin endocytosis and recycling Ion channel transport	Pathway 2	Drugs 1 Tiludronic acid	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols ALK and TSPAN16	Name 1 ALK receptor tyrosine kinase	Name2 tetraspanin 16	Pathway 1 Signaling by ALK Signaling by ALK ALK mutants bind TKIs ASP-3026-resistant ALK mutants NVP-TAE684-resistant ALK mutants alectinib-resistant ALK mutants brigatinib-resistant ALK mutants ceritinib-resistant ALK mutants crizotinib-resistant ALK mutants lorlatinib-resistant ALK mutants Signaling by ALK fusions and activated point mutants MDK and PTN in ALK signaling MDK and PTN in ALK signaling	Pathway 2	Drugs 1 ATP Crizotinib Ceritinib Alectinib Fostamatinib Lorlatinib Gilteritinib Brigatinib	Drugs 2	Diseases 1 Non-small cell lung cancer	Diseases 2
Novel	Symbols C5 and SLC10A2	Name 1 complement C5	Name2 solute carrier family 10 member 2	Pathway 1 Terminal pathway of complement Activation of C3 and C5 Peptide ligand-binding receptors G alpha (i) signalling events Regulation of Complement cascade	Pathway 2 Recycling of bile acids and salts	Drugs 1 Human immunoglobulin G Eculizumab Zinc Copper Ravulizumab Zinc acetate Zinc chloride Zinc sulfate, unspecified form Zilucoplan Vilobelimab	Drugs 2 Volixibat Maralixibat Odevixibat	Diseases 1 Late complement pathway defects, including the following seven diseases: C5 deficiency; C6 deficiency; C7 deficiency; C8 alpha-chain deficiency; C8 beta-chain deficiency; C8 gamma-chain deficiency; C9 deficiency	Diseases 2 Primary bile acid malabsorption
Novel	Symbols ICAM1 and MC1R	Name 1 intercellular adhesion molecule 1	Name2 melanocortin 1 receptor	Pathway 1 Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Integrin cell surface interactions Interleukin-10 signaling Interleukin-4 and Interleukin-13 signaling Interferon gamma signaling	Pathway 2 Peptide ligand-binding receptors G alpha (s) signalling events Transcriptional and post-translational regulation of MITF-M expression and activity	Drugs 1 Natalizumab Hyaluronic acid Nafamostat	Drugs 2 Afamelanotide CZEN 002 Bremelanotide	Diseases 1 Allograft rejection	Diseases 2
Novel	Symbols RAE1 and RTEL1	Name 1 ribonucleic acid export 1	Name2 regulator of telomere elongation helicase 1	Pathway 1 ISG15 antiviral mechanism Transport of the SLBP independent Mature mRNA Transport of the SLBP Dependant Mature mRNA Transport of Mature mRNA Derived from an Intronless Transcript Transport of Mature mRNA derived from an Intron-Containing Transcript Rev-mediated nuclear export of HIV RNA Transport of Ribonucleoproteins into the Host Nucleus NS1 Mediated Effects on Host Pathways Viral Messenger RNA Synthesis NEP/NS2 Interacts with the Cellular Export Machinery Regulation of Glucokinase by Glucokinase Regulatory Protein Nuclear import of Rev protein Vpr-mediated nuclear import of PICs IPs transport between nucleus and cytosol IP3 and IP4 transport between cytosol and nucleus IP6 and IP7 transport between cytosol and nucleus snRNP Assembly SUMOylation of DNA damage response and repair proteins SUMOylation of ubiquitinylation proteins Nuclear Pore Complex (NPC) Disassembly Regulation of HSF1-mediated heat shock response SUMOylation of SUMOylation proteins SUMOylation of chromatin organization proteins SUMOylation of RNA binding proteins SUMOylation of DNA replication proteins SUMOylation of DNA replication proteins Transcriptional regulation by small RNAs Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) tRNA processing in the nucleus HCMV Early Events HCMV Late Events SARS-CoV-2 activates/modulates innate and adaptive immune responses	Pathway 2 Telomere Extension By Telomerase Cytosolic iron-sulfur cluster assembly Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols TRIM31 and BTNL2	Name 1 tripartite motif containing 31	Name2 butyrophilin like 2	Pathway 1 Interferon gamma signaling	Pathway 2 Butyrophilin (BTN) family interactions	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols ACTR1A and CNNM2	Name 1 actin related protein 1A	Name2 cyclin and CBS domain divalent metal cation transport mediator 2	Pathway 1 MHC class II antigen presentation Regulation of PLK1 Activity at G2/M Transition HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Anchoring of the basal body to the plasma membrane COPI-mediated anterograde transport COPI-independent Golgi-to-ER retrograde traffic AURKA Activation by TPX2	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols FBN1 and SECISBP2L	Name 1 fibrillin 1	Name2 SECIS binding protein 2 like	Pathway 1 Degradation of the extracellular matrix Degradation of the extracellular matrix Elastic fibre formation Molecules associated with elastic fibres Molecules associated with elastic fibres Integrin cell surface interactions TGF-beta receptor signaling activates SMADs Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Post-translational protein phosphorylation	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Geleophysic dysplasia Weill-Marchesani syndrome, including: Weill-Marchesani syndrome; Weill-Marchesani-like syndrome Shprintzen-Goldberg syndrome Ectopia lentis MASS phenotype Marfan syndrome, including: Marfan syndrome (MFS); Neonatal MFS; Atypically severe MFS; New variant of MFS	Diseases 2

Page 3 out of 98 pages

Search Results : Cancer